Edaravone Dexborneol Improves Functional Outcome in AIS Patients Undergoing EVT

Background: For decades, the stroke community has tried a medication that can protect brain tissue during acute ischemic events to save as many neurons as possible. The TASTE-2 (Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol-II) is one of the latest attempts to find a neuroprotector agent in the treatment of acute ischemic stroke (AIS). Objective: To evaluate the efficacy and safety of edaravone dexborneol in enhancing functional outcome for patients with AIS undergoing endovascular thrombectomy (EVT) owing to large vessel occlusion. Design/Participants: Multicenter, double-blind, randomized, placebo-controlled trial including patients with AIS. Methods: The authors tested the theory that edaravone dexborneol would be superior to placebo in achieving good clinical functional outcomes (defined as a modified Rankin Scale [mRS] score of 0 to 2) at 90 days. Patients could receive alteplase, if indicated, and they had to get mechanical EVT to participate. Patients had to en more...